Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of EDP-938 in Infants and Young Children with RSV Infection
2020-001966-13Phase 2Completed
- Sponsor
- Enanta Pharmaceuticals, Inc.
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zelicapavir in respiratory syncytial virus disease (RSV) (4 arms), sponsored by Enanta Pharmaceuticals, Inc. Primary endpoint: Primary endpoints (Part 1). Started Feb 2021; status: completed.
02
Drugs
zelicapavir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2020-001966-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001966-13.